Stock Track | Stoke Therapeutics Plunges 6.08% After Hours on Mixed Q3 Results and Wider-than-Expected Loss

Stock Track11-05

Shares of Stoke Therapeutics, Inc. (STOK) tumbled 6.08% in after-hours trading on Tuesday following the release of its third-quarter 2025 financial results. Despite reporting higher-than-expected revenue, the company's wider-than-anticipated loss per share appears to have disappointed investors.

Stoke Therapeutics reported Q3 revenue of $10.632 million, significantly surpassing the IBES estimate of $5.51 million. This represents a substantial 117.2% increase from the same quarter last year. However, the company posted a quarterly adjusted loss of 65 cents per share, which was larger than the mean analyst expectation of a 57 cents per share loss.

While Stoke Therapeutics highlighted its strong cash position of $328.6 million as of September 30, which is anticipated to fund operations through mid-2028, investors seemed more focused on the increased operating expenses. The company's operating expenses rose to $53.723 million for the quarter, with research and development expenses climbing to $96.2 million for the nine-month period, up from $65.7 million in the previous year. Despite the negative market reaction, Stoke Therapeutics emphasized ongoing progress in its clinical trials, including patient recruitment for the Phase 3 EMPEROR study of zorevunersen in the U.S., UK, and Japan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1127674772?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 05:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127674772","market":"nz","top_or_hot":-1,"title":"Stock Track | Stoke Therapeutics Plunges 6.08% After Hours on Mixed Q3 Results and Wider-than-Expected Loss","media":"Stock Track","content":"<p>Shares of Stoke Therapeutics, Inc. (STOK) tumbled 6.08% in after-hours trading on Tuesday following the release of its third-quarter 2025 financial results. Despite reporting higher-than-expected revenue, the company's wider-than-anticipated loss per share appears to have disappointed investors.</p>\n\n<p>Stoke Therapeutics reported Q3 revenue of $10.632 million, significantly surpassing the IBES estimate of $5.51 million. This represents a substantial 117.2% increase from the same quarter last year. However, the company posted a quarterly adjusted loss of 65 cents per share, which was larger than the mean analyst expectation of a 57 cents per share loss.</p>\n\n<p>While Stoke Therapeutics highlighted its strong cash position of $328.6 million as of September 30, which is anticipated to fund operations through mid-2028, investors seemed more focused on the increased operating expenses. The company's operating expenses rose to $53.723 million for the quarter, with research and development expenses climbing to $96.2 million for the nine-month period, up from $65.7 million in the previous year. Despite the negative market reaction, Stoke Therapeutics emphasized ongoing progress in its clinical trials, including patient recruitment for the Phase 3 EMPEROR study of zorevunersen in the U.S., UK, and Japan.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Stoke Therapeutics Plunges 6.08% After Hours on Mixed Q3 Results and Wider-than-Expected Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Stoke Therapeutics Plunges 6.08% After Hours on Mixed Q3 Results and Wider-than-Expected Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 05:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Stoke Therapeutics, Inc. (STOK) tumbled 6.08% in after-hours trading on Tuesday following the release of its third-quarter 2025 financial results. Despite reporting higher-than-expected revenue, the company's wider-than-anticipated loss per share appears to have disappointed investors.</p>\n\n<p>Stoke Therapeutics reported Q3 revenue of $10.632 million, significantly surpassing the IBES estimate of $5.51 million. This represents a substantial 117.2% increase from the same quarter last year. However, the company posted a quarterly adjusted loss of 65 cents per share, which was larger than the mean analyst expectation of a 57 cents per share loss.</p>\n\n<p>While Stoke Therapeutics highlighted its strong cash position of $328.6 million as of September 30, which is anticipated to fund operations through mid-2028, investors seemed more focused on the increased operating expenses. The company's operating expenses rose to $53.723 million for the quarter, with research and development expenses climbing to $96.2 million for the nine-month period, up from $65.7 million in the previous year. Despite the negative market reaction, Stoke Therapeutics emphasized ongoing progress in its clinical trials, including patient recruitment for the Phase 3 EMPEROR study of zorevunersen in the U.S., UK, and Japan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"STOK","symbol_name":"Stoke Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1127674772","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127674772","pubTimestamp":1762291991,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Stoke Therapeutics, Inc. (STOK) tumbled 6.08% in after-hours trading on Tuesday following the release of its third-quarter 2025 financial results. Despite reporting higher-than-expected...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"STOK":"Stoke Therapeutics, Inc."},"translate_title":"个股追踪|Stoke Therapeutics盘后暴跌6.08%Q3业绩好坏参半亏损超预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STOK":1},"content_text":"Shares of Stoke Therapeutics, Inc. (STOK) tumbled 6.08% in after-hours trading on Tuesday following the release of its third-quarter 2025 financial results. Despite reporting higher-than-expected revenue, the company's wider-than-anticipated loss per share appears to have disappointed investors.\nStoke Therapeutics reported Q3 revenue of $10.632 million, significantly surpassing the IBES estimate of $5.51 million. This represents a substantial 117.2% increase from the same quarter last year. However, the company posted a quarterly adjusted loss of 65 cents per share, which was larger than the mean analyst expectation of a 57 cents per share loss.\nWhile Stoke Therapeutics highlighted its strong cash position of $328.6 million as of September 30, which is anticipated to fund operations through mid-2028, investors seemed more focused on the increased operating expenses. The company's operating expenses rose to $53.723 million for the quarter, with research and development expenses climbing to $96.2 million for the nine-month period, up from $65.7 million in the previous year. Despite the negative market reaction, Stoke Therapeutics emphasized ongoing progress in its clinical trials, including patient recruitment for the Phase 3 EMPEROR study of zorevunersen in the U.S., UK, and Japan.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1127674772","isCrawlerRequest":true}